Clovis Oncology announces interim results for drug treating pancreatic cancer
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced interim results from an investigator-initiated Phase 2 trial of Rubraca (rucaparib) in platinum-sensitive patients with advanced... Read More
Tuesday April 2, 2019 0 comments
Clovis Oncology: Rubraca now available in Germany for ovarian cancer therapy
BOULDER MUNICH -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced Rubraca (rucaparib) is now available by prescription in Germany as monotherapy for the maintenance treatment of adults with... Read More
Tuesday March 5, 2019 0 comments
Clovis Oncology announces European Commission OK of Rubraca for ovarian cancer
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the European Commission (EC) has approved the use of Rubraca(rucaparib) for treatment of ovarian cancer. Specifically, the... Read More
Monday January 28, 2019 0 comments
Clovis Oncology announces positive hearing for Rubraca in Europe
BOULDER -- Clovis Oncology, Inc. (NASDAQ:CLVS) today announced after opposition proceedings at The Hague, Netherlands, that the European Patent Office upheld claims of European Patent 2534153... Read More
Wednesday December 5, 2018 0 comments
Clovis Oncology announces second patent for Rucaparib high dose
BOULDER -- Clovis Oncology , Inc. (NASDAQ:CLVS) today announced the United States Patent and Trademark Office issued United States Patent 10,130,636 with claims directed to methods of treating... Read More
Tuesday November 20, 2018 0 comments
Clovis Oncology receives Breakthrough Therapy designation for Rubraca
BOULDER -- Clovis Oncology, Inc. (NASDAQ: CLVS) today announced theU.S. Food and Drug Administration(FDA) has granted Breakthrough Therapy designation for Rubraca (rucaparib) as a monotherapy... Read More
Tuesday October 2, 2018 0 comments
Clovis Oncology announces first patient enrolled in cancer trial
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) today announced the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis Rubraca (rucaparib), a... Read More
Wednesday August 8, 2018 0 comments
Clovis Oncology receives European validation for Rubraca cancer drug
BOULDER -- Clovis Oncology, Inc . (NASDAQ: CLVS) announced the European Medicines Agency (EMA) has validated the application for a Type II variation to the marketing authorization for Rubraca ... Read More
Thursday July 5, 2018 0 comments
IN Sponsors
Browse
Entrepreneurial by Nature
